Evaluation of two staging systems for HIV infection for use in developing countries

Area of Science:

• Immunology
• Infectious Diseases
• Public Health

Background:

• Human Immunodeficiency Virus (HIV) infection staging is crucial for patient management and treatment decisions.
• Current staging often relies on CD4 lymphocyte counts, which can be resource-intensive.
• The World Health Organization (WHO) clinical staging system provides a framework for assessing HIV disease progression.

Purpose of the Study:

• To evaluate the clinical axis of the WHO staging system and a modified version by Montaner et al.
• To compare these staging systems using specific lymphocyte strata (>1500, 1500-1000, <1000 cells x 10(6)/l).
• To assess the utility of these systems as alternatives to CD4 count-based staging.

Main Methods:

• A cross-sectional study involving 415 consecutive HIV-infected patients from three Belgian centers.
• Comparison of absolute CD4 lymphocyte counts between different stages within the WHO and modified WHO staging systems.
• Statistical analysis using Kruskal-Wallis one-way analysis of variance.

Main Results:

• Median CD4 lymphocyte counts significantly decreased with advancing disease stage in both systems (P < 0.001).
• WHO stage 1 and modified WHO stage I showed positive predictive values of 56% and 58% for CD4 counts >500 cells x 10(6)/l.
• WHO stage 4 and modified WHO stage IV demonstrated positive predictive values of 79% and 80% for CD4 counts <200 cells x 10(6)/l.

Conclusions:

• The WHO clinical staging system and its modified version are valuable tools for HIV staging.
• These systems may serve as effective alternatives to CD4 lymphocyte count-based staging, particularly in developing countries.
• Further cohort studies in developing countries are recommended to confirm their prognostic value.